bluuebunny/crossref_metadata_2025_split huggingface dataset:
A systematic review of gender diversity and its impact on the performance of Microfinance Institutions
Authors: Hossain Md Imran , Mia Md Aslam , Dalla Pellegrina Lucia 
Published: January 2024

AbstractThis study aims to consolidate the available knowledge on gender diversity and its impact on the dual performance (social and financial) of Microfinance Institutions (MFIs). We specifically focus on MFIs due to their distinctive nature compared to other industries, being traditionally women-centered and having a substantial representation of women employees across all levels of the corporate hierarchy. To conduct this comprehensive analysis, we employed a systematic review approach, meticulously selecting 24 relevant papers from the Scopus and Web of Science databases. Our findings revealed that research on gender diversity in MFIs primarily focuses on the board level. However, existing studies present conflicting results, suggesting that the impact of gender diversity on MFI performance is nuanced and complex. This complexity stems largely from the varying roles women play within the organizational structure. Furthermore, our analysis highlights the influence of additional factors, such as the database used, the study's context, and its geographical location, on the reported outcomes. Notably, research on gender diversity at the managerial and loan officer levels remains scarce, presenting a significant gap in the current body of knowledge. To further illuminate this field, this study identifies the most influential papers on the topic of gender diversity in microfinance. Additionally, we provide a co-authorship network analysis, visualizing the connections between existing research. This analysis provides valuable insights and inspiration for future research endeavors in this critical area.
Network analysis uncovers the master role of WRKY transcription factors in
Arabidopsis thaliana
response to
N
-acyl homoserine lactones
Authors: Duan Yongming , Han Min , Grimm Maja , Schikora Adam 
Published: January 2024

Abstract

Background

Plants can perceive bacterial molecules such as the quorum sensing signals
N
-acyl homoserine lactones (AHL), thus modifying their fitness in response to environmental factors. Even though the benefits conferred by AHL depend on various hormone signaling pathways, the understanding of AHL signaling, especially the response to AHL presence, remains largely unknown.

Methods
Weighted gene co-expression network analysis (WGCNA), multi-omics network analysis, and reverse transcription quantitative PCR (RT-qPCR) assays were used to identify key genes in AHL signaling.

Results

To obtain comprehensive insights on AHL signaling, we integrated available transcriptome data from
Arabidopsis thaliana
exposed to different single or multiple AHL molecules and performed a weighted gene co-expression network analysis. We identified several key genes regulated in plants exposed to multiple AHL molecules. Multi-omics network analysis and RT-qPCR assay revealed a potential role of WRKY transcription factors.

Conclusions
Results presented here offer good indications for exploring the mechanism of plants' response to bacterial signaling molecules, which could further support the application of AHL-producing bacteria in sustainable agriculture.
Poor Concordance Between Cancer Antigen-125 and RECIST Assessment for Progression in Patients With Platinum-Sensitive Relapsed Ovarian Cancer on Maintenance Therapy With a Poly(ADP-ribose) Polymerase Inhibitor
Authors: Tjokrowidjaja Angelina , Friedlander M.L. , Ledermann Jonathan A. , Coleman Robert L. , Mirza Mansoor R. , Matulonis Ursula A. , Pujade-Lauraine Eric , Lord Sarah J. , Scott Clare L. , Goble Sandra , York Whitney , Lee Chee K. ,   on behalf of the Gynecologic Cancer Intergroup Meta-Analysis Committee, Khoon Lee Chee , You Benoit , Paoletti Xavier , Glasspool Ros , Friedlander Michael , Scott Clare , Mirza Monsoor , Pujade Lauraine Eric , Ledermann Jonathan , Antill Yoland , Mileshkin Linda , Ethier Josee-Lyne , Bookman Michael , Gourley Charlie 
Published: January 2024

PURPOSE Cancer antigen-125 (CA-125) is recommended by treatment guidelines and widely used to diagnose ovarian cancer recurrence. The value of CA-125 as a surrogate for disease progression (PD) and its concordance with radiologic progression are unclear, particularly for women with platinum-sensitive relapsed ovarian cancer (PSROC) who have responded to chemotherapy and treated with maintenance poly(ADP-ribose) polymerase inhibitor (PARPi). METHODS In this pooled analysis of four randomized trials of maintenance PARPi or placebo (Study 19, SOLO2, ARIEL3, and NOVA), we extracted data on CA-125 PD as defined by Gynecologic Cancer InterGroup criteria and RECIST v1.1. We evaluated the concordance between CA-125 and RECIST PD and reported on the negative predictive value (NPV) and positive predictive value (PPV). RESULTS Of 1,262 participants (n = 818 PARPi, n = 444 placebo), 403 (32%) had CA-125 PD, and of these, 366 had concordant RECIST PD (PPV, 91% [95% CI, 88 to 93]). However, of 859 (68%) without CA-125 PD, 382 also did not have RECIST PD (NPV, 44% [95% CI, 41 to 48]). Within the treatment arms, PPV remained high (PARPi, 91% [95% CI, 86 to 94]; placebo, 91% [95% CI, 86 to 95]) but NPV was lower on placebo (PARPi, 53% [95% CI, 49 to 57]; placebo, 25% [95% CI, 20 to 31]). Of 477 with RECIST-only PD, most (95%) had a normal CA-125 at the start of maintenance therapy and the majority (n = 304, 64%) had CA-125 that remained within normal range. Solid organ recurrence without peritoneal disease was more common in those with RECIST-only PD than in those with CA-125 and RECIST PD (36% v 24%; P < .001). CONCLUSION In patients with PSROC treated with maintenance PARPi, almost half with RECIST PD did not have CA-125 PD, challenging current guidelines. Periodic computed tomography imaging should be considered as part of surveillance, particularly in those with a normal CA-125 at the start of maintenance therapy and on treatment.
Patient-Reported Outcomes in Patients With Advanced Urothelial Cancer Who Are Ineligible for Cisplatin and Treated With First-Line Enfortumab Vedotin Alone or With Pembrolizumab
Authors: Milowsky Matthew I. , O'Donnell Peter H. , Hoimes Christopher J. , Petrylak Daniel P. , Flaig Thomas W. , Moon Helen H. , Friedlander Terence W. , Mar Nataliya , McKay Rana R. , Srinivas Sandy , Gravis Gwenaelle , Ramamurthy Chethan , Bupathi Manojkumar , Bracarda Sergio , Wright Phoebe , Hepp Zsolt , Carret Anne-Sophie , Yu Yao , Dillon Ryan , Kataria Ritesh , Beaumont Jennifer L. , Purnajo Intan , Rosenberg Jonathan E. 
Published: January 2024

PURPOSE Locally advanced/metastatic urothelial cancer (la/mUC) affects patients' quality of life (QOL) and functioning. We describe the impact of first-line (1L) enfortumab vedotin (EV) alone or with pembrolizumab (P) on QOL/functioning/symptoms in patients with la/mUC who were cisplatin-ineligible from EV-103 Cohort K. METHODS In this phase Ib/II trial, patients were randomly assigned 1:1 to EV + P or EV monotherapy (mono). Exploratory patient-reported outcomes (PROs) were assessed using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire–Core Questionnaire (EORTC QLQ-C30) and Brief Pain Inventory Short Form (BPI-SF) at baseline, once per week for cycles 1-3, and then in every cycle through the end of treatment. Changes in scores from baseline to week 24, reported as least squares mean (standard error), were assessed by mixed models for repeated measures. There were no formal statistical comparisons between treatment arms. RESULTS Of 149 patients treated, 65 (EV + P) and 63 (EV mono) comprised the PRO analysis set. For EV + P, EORTC QLQ-C30 QOL was maintained through week 24 with improvements in emotional functioning, pain, and insomnia. Clinically meaningful improvements were seen in EORTC QLQ-C30 pain after EV + P at weeks 12 (–14.41 [3.14]) and 24 (–14.99 [3.56]) and BPI-SF worst pain at week 24 (–2.07 [0.37]). For EV mono, EORTC QLQ-C30 QOL remained stable with clinically meaningful improvements in EORTC QLQ-C30 pain (–12.55 [4.27]), insomnia (–14.46 [4.69]), and constipation (–10.09 [4.35]) at week 24. There were small-to-moderate improvements in BPI-SF worst pain at week 24. CONCLUSION EV + P in patients with la/mUC who were cisplatin-ineligible was associated with preservation or improvement of QOL/functioning/symptoms. Improvement in pain was seen in both PRO instruments and treatment arms. These data complement clinical outcomes of 1L EV + P.
Function phononic crystals
Authors: Röhlig David , Kuhn Eduard , Teichert Fabian , Thränhardt Angela , Blaudeck Thomas 
Published: January 2024

Abstract
We propose a novel type of phononic crystal for which the materials parameters are continuous functions of space coordinates without discontinuities corresponding to a seamless fusion of the constituent materials within the crystal lattice. With the help of an adaptation of this fundamental approach, we extend the well-established concept of phononic crystals, allowing an investigation of the transition from conventional phononic crystals with a regulated step-like parameter function to the realm of so-called function phononic crystals. Our study is based on a first-principle theory assisted by high-performance computer simulations and focuses on an understanding of the effects of a deviation from the typical parameter step function on the phononic density of states (DOS). Our exploration of the DOS reveals a characteristic rapid convergence: even a slight deviation from an ideal step function has the potential to induce radical changes in the band structure leading to the emergence of desirable features, especially multiple complete phononic band gaps.
Optimal Cumulative I-131 Activity in Metastatic Differentiated Thyroid Cancer: Balancing Efficacy and Adverse Events
Authors: Bharadwaj Mangu Srinivas , Ballal Sanjana , Bal Chandrasekhar 
Published: January 2024

Abstract

Background
The optimal cumulative activity (CA) of I-131 therapy for patients with metastatic differentiated thyroid cancer (mDTC) remains contentious. This study aimed to determine the maximum CA of I-131 that could be administered without a significant increase in adverse events (AEs) by analyzing a long-term cohort of patients.

Methods
Data from patients with mDTC treated with I-131 therapy and followed for at least 2 years from 1967 to 2019 were reviewed. Patients were categorized into 3 groups based on the received CA: group A (≤600 mCi), group B (&gt;600-1000 mCi), and group C (&gt;1000 mCi). The study assessed long-term AEs and survival outcomes.

Results
The study included 671 adult patients with mDTC (mean age, 48 years; range, 19-81) with a median follow-up of 122 months (interquartile range: 82-180). Group A, group B, and group C comprised 269 (40.0%), 212 (31.6%), and 190 (28.4%) patients, respectively. Ten-year survival rates were 72%, 42.7%, and 29% in groups A, B, and C, respectively. A total of 40/671 (6%) AEs were observed in 38 patients: 3 (1.1%), 12 (5.7%), and 25 (13.2%) in groups A, B, and C, respectively. Five patients developed second primary malignancy: 3 in group A and 1 each in group B and C. However, CA &gt;1000 mCi of I-131 was associated with significant increase in bone marrow suppression, decreased pulmonary function, and xerostomia (P &lt; .001).

Conclusion
The study suggests that a maximum CA of up to 1000 mCi strikes a favorable balance between keeping AEs low and benefiting a subset of patients with extensive metastases showing intense I-131 concentration.
Pituitary Macroadenoma With Macronodular Adrenal Hyperplasia and Novel Armadillo Repeat-Containing Protein 5 (ARMC5) Mutation
Authors: Khosla Shikha , Alsarraf Farah , Nylen Eric S 
Published: January 2024

Abstract
We present an unusual case of primary bilateral macronodular adrenal hyperplasia (PBMAH) in a 72-year-old African American man. The patient was found to harbor massively enlarged bilateral adrenal glands on imaging along with mild autonomous cortisol secretion. His workup for PBMAH included leukocyte analysis for the armadillo repeat-containing protein 5 (ARMC5) gene. The test revealed a novel heterozygous somatic ARMC5 mutation. The patient was initially managed conservatively. He subsequently presented with unprovoked bilateral pulmonary emboli. This was followed by the discovery of a nonsecreting pituitary macroadenoma, a hitherto unreported but putative association.
P-15 A rare case of Trichorhinophalangeal Syndrome Type I
Authors: Akçura Can , Alkan Samet , Güney Sedat Can , Aykut Ayça , Durmaz Asude , Özdemir Nilüfer , Hekimsoy Zeliha 
Published: January 2024

Abstract

Introduction
Trichorhinopharyngeal syndrome (TRPS) type 1 is a rare autosomal dominant genetic disorder due to defects of the TRPS1 gene. Clinical findings include short stature, fine hair, craniofacial and skeletal malformations, and deformities in phalangeal joints. This rare disease has a wide clinical spectrum and careful investigation on suspected cases should be made.

Clinical Case
A 19-year-old female patient, after application to the rheumatology clinic of our center with hand deformities, was referred to our endocrinology clinic after initial examination revealed no rheumatologic disorder; with a pre-diagnosis of a possible bone mineral disorder. She had no co-morbid disease, but her history revealed admissions to a pediatric endocrinology unit and investigations of a possible mucopolysaccharidosis, though no diagnosis had been made. There was no kinship between her parents. In her physical examination, she had fine hair, the fifth metacarpal bone of her right hand was short, she had palpable bone cysts on both of her third phalanges, and a high palatal arch. She had a short stature of 149 cm. From her history, it was learned that none of her relatives showed similar phenotypic properties. Her laboratory findings, listed in Table 1, showed no definitive defect other than a mild vitamin D deficit. The X-ray of her hands (Figure 1) showed shortening of the right fifth metacarpal bone. Her bone mineral density scan was normal. From this point, due to her clinical and radiological findings, a possible diagnosis of pseudo-pseudohypoparathyroidism was assumed, and the patient was referred to the department of genetics. The result of the genetic analysis revealed a heterozygous c.2894G&gt;A (p.Arg965His) variant in the TRPS1 (NM_014112/5) gene. As a result, the patient was diagnosed with trichorhinophalangeal syndrome type 1, and was referred to the department of physical medicine and rehabilitation for physiotheraphy program for her hand deformities and possible future deformities in the skeletal system. Because the disease has an autosomal dominant inheritance, she was also informed about genetic consultancy for her possible future conception.

Conclusion
Trichorhinophalangeal syndrome type 1 is a rare disease and can mimic a variety of disorders including pseudo-pseudohypoparathyroidism, rheumatoid arthritis and other rheumatological diseases. Though there is no definite treatment, suspected cases should be evaluated both clinically and genetically to avoid misdiagnosis.
Financial disclosures: None
Funding resources: NoneFigure 1.X-ray of the patient's handsArrow shows shortening of the right fifth metacarpal bone Table 1.Laboratory findings of the patientALT: alanine aminotransferase, ALP: alkaline phosphatase, PTH: parathormone
P-24 Intriguing association between type 1 diabetes mellitus, Gitelman syndrome and Cacci Ricci disease: Triad of rare diseases
Authors: Elfekih Hamza , Bnina Molka Ben , Abdessalem Fatma Ben , Gorchene Asma , Ach Koussay , Hasni Yosra , Chaieb Molka 
Published: January 2024

Abstract

Introduction
Type 1 diabetes mellitus (T1DM) is known to be associated with other autoimmune diseases. Nevertheless, medical conditions can coexist in unexpected ways. Such is the case of a rare and fascinating occurrence, where a patient was diagnosed with T1DM, Gitelman syndrome and Cacci Ricci disease.

Clinical Case
A 27-year-old male patient was suspected to have Gitelman syndrome at the age of 3 years in the presence of tetany crisis, abdominal pain and severe hypokalemia at 1,4 mmol/L. The diagnosis was confirmed by genetic testing highlighting a mutation in the SLC12A3 gene that codes for the sodium-chloride cotransporter. Abdominal pain disappeared after potassium and magnesium supplementation and the repercussion of Gitelman's syndrome was growth retardation. Diabetic ketoacidosis decompensation due to T1DM was developed. He had poor glycemic control although intensified insulin protocol. Cacci Ricci's disease was revealed by terminal hematuria. Abdomino-pelvic CT-scan objectified precalicial canalicular ectasia with bilateral nephrocalcinosis and about twenty non obstructing bilateral micro-nephrolithiasis. Serum calcium, phosphorus and PTH levels were in the normal range.

Conclusion
The coexistence of T1DM, Gitelman syndrome, and Cacci Ricci disease in the same patient remains a fascinating medical mystery. Abnormalities in certain ion channels and transporters could affect multiple systems leading to the manifestation of seemingly unrelated conditions in a single patient. As research continues, healthcare professionals hope to gain a better understanding of the underlying mechanisms and develop more effective treatment strategies for these rare and complex cases.
P-60 Opioid induced secondary adrenal insufficiency: A case report
Authors: Rocha José Vicente , Lopes Marta Vaz , Peixe Carolina , De Griné Severino Mariana , Alexandre Maria Inês , Gomes Ana Coelho , Bugalho Maria João 
Published: January 2024

Abstract

Introduction
Opioid treatment is common and useful in acute pain management, but long-term opioid treatment is not routinely recommended. Opioids influence the endocrine system by blunting the hypothalamic–pituitary–adrenal (HPA) axis: as ACTH is synthesized from the same precursor protein as beta-endorphins, opioids lower serum cortisol and supress cortisol response through a mechanism of negative feedback. In the same way, naloxone infusion leads to an increase in serum cortisol.

Clinical Case
A forty-nine-year-old woman was sent to an endocrinology appointment due to altered serum cortisol measurements. She had a past history of Graves’ disease currently in clinical and biochemical remission. Her history was also notable for chronic obstructive pulmonary disease under inhaled corticosteroids and previous toxicophilic habits under methadone replacement treatment.
The patient was asymptomatic with a laboratory evaluation of the HPA axis suggestive of adrenal insufficiency –morning serum cortisol measurements persistently under 10μg/dL. Stimulation test with cosyntropin showed an insufficient response with a peak cortisol of 12 μg/dL, confirming adrenal insufficiency.
As the patient had no clinical signs of adrenal insufficiency and was maintained under inhaled corticosteroid treatment, she was given an emergency glucocorticoid card and was instructed to take replacement treatment with hydrocortisone in stress situations.

Conclusion
In this patient, the HPA axis suppression might have been multifactorial resulting from inhaled glucocorticoids and chronic opioid use. Opioids are very common drugs and adrenal insufficiency is probably more frequent than it is accounted for in this population, with unspecific symptoms but possible serious consequences. Therefore, patients under opioid treatment with suggestive symptoms might benefit from adrenal insufficiency exclusion.
Standard versus mini amplatz size in patients undergoing pediatric percutaneous nephrolithotomy through 16 years of experience: A retrospective study in single-center experience
Authors: Rasyid Nur , Fadhly Syifa Fauziah , Atmoko Widi , Birowo Ponco 
Published: January 2024

Background: Pediatric urolithiasis is associated with considerable morbidity and a very high recurrence rate of approximately 67%. Current guideline recommendations for standard pediatric percutaneous nephrolithotomy (PCNL) remain a problem due to several complications, such as hemorrhage or renal damage, especially in the pediatric population. However, mini-PCNL is regarded as a safer and more effective method for pediatric patients. This study compares PCNL with mini-PCNL, along with their efficacy and safety, in the Cipto Mangunkusumo General Hospital, Indonesia. Methods: This observational retrospective study was performed on pediatric patients aged < 18 years (pediatric patients) who underwent PCNL with a standard 22-30 Fr sheath or mini 15-21 Fr sheath. We reviewed postoperative outcomes, including stone-free rate (SFR), presence of complications, and postoperative drainage method. Data analysis was performed using SPSS version 26.0. Results: Our study included a total of 42 pediatric patients (mean age: standard, 4.61 ± 3.52 years; mini, 8.0 ± 3.57 years; p<0.05). The stone-free rate was significantly higher in the mini-PCNL group (87.9%) than in the standard PCNL group (59.1%, p <0.05). All patients treated with mini-PCNL were tubeless, while some patients in the standard group still needed a postoperative drainage tube (p=0.012). Complications, such as infundibulum laceration, were rare, and their differences between groups insignificant (p=1). Even though it has been demonstrated that standard sheath PCNL is considered effective for children, smaller PCNL sheaths offers more experience. Mini-PCNL provides a similar complication rate, while remaining effective in treating urolithiasis; thus, it is thought to be a non-inferior option for treating pediatric populations, especially younger and smaller children. Conclusions: Mini-PCNL is non-inferior to standard PCNL in terms of efficacy and safety for the treatment of pediatric urolithiasis. Mini-PCNL resulted in higher SFR and totally tubeless follow-up.
Role of Metformin in Polycystic Ovary Syndrome
Authors: Nowak Karolina , Nowak Karolina , Olejarz Zuzanna , Drygała Zuzanna , Wyrwał Julia , Zielińska Zuzanna , Słowik Magdalena , Nieć Maria , Gierlach Katarzyna , Krasuska Martyna 
Published: January 2024

Introduction and purpose:
PCOS is identified by the presence of underdeveloped follicles in the ovaries caused by a lack of ovulation, and it is linked to heightened production of androgens in the ovaries. The observable symptoms of PCOS encompass irregular or absent menstrual cycles, obesity, and indications of excess androgens such as acne or oily skin. Metformin could be advantageous for a specific group of women with PCOS.
The aim of this study is to summarize the current knowledge regarding the effectiveness of metformin in the treatment of PCOS based on available scientific literature.
A brief description of the state of knowledge:Metformin indirectly aids in enhancing ovulation and alleviating long-term metabolic issues, although its impact is considered moderate. Metformin also diminishes the levels of particular markers linked to arterial issues and chronic inflammation beneath the surface. This indicates a potential decrease in the continual risks of type 2 diabetes (DM) and cardiovascular disease (CVD) for women dealing with PCOS.
Summary (conclusions):

Managing PCOS involves personalized targets due to its diverse nature. In clinical practice, metformin is a recommended first step for managing PCOS in overweight or obese patients, particularly when oral contraceptives are not suitable or insulin resistance is evident.